Clinical Management of Uterine Fibroids

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Obstetrics & Gynecology".

Deadline for manuscript submissions: 30 April 2024 | Viewed by 1146

Special Issue Editor


E-Mail Website
Guest Editor
Department of Radiology, Rutgers New Jersey Medical School, Newark, NJ, USA
Interests: general interventional radiology

Special Issue Information

Dear Colleagues,

We are calling for submissions discussing up-to-date management paradigms for patients with symptomatic uterine fibroids. Original research and review articles are welcome. The scope of the issue is all-encompassing and can include epidemiology, clinical work-up, imaging diagnoses, pathophysiology and histology, treatment options (medical management, surgical options, interventional radiology), fertility issues, and future directions for treatment.

Dr. Pratik A. Shukla
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • uterine fibroids
  • menorrhagia
  • leiomyoma
  • symptomatic anemia
  • hysterectomy
  • myomectomy
  • uterine fibroid embo-lization
  • high-intensity focused ultrasound
  • fertility

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

11 pages, 266 KiB  
Article
Occurrence and Risk Factors for Perioperative Treatment Discontinuation during Magnetic Resonance-Guided High-Intensity Focused Ultrasound (MR-HIFU) Therapy in Symptomatic Uterine Fibroids—A Retrospective Case–Control Study
by Jakub Kociuba, Tomasz Łoziński, Kamil Latra, Lidia Korczyńska, Artur Skowyra, Elżbieta Zarychta and Michał Ciebiera
J. Clin. Med. 2023, 12(18), 5999; https://doi.org/10.3390/jcm12185999 - 16 Sep 2023
Viewed by 793
Abstract
Background: The main aim of our study involves the analysis of reasons and risk factors for perioperative treatment discontinuation in patients with symptomatic uterine fibroids (UFs) who were qualified for magnetic resonance-guided high-intensity focused ultrasound (MR-HIFU) and in whom the procedure was discontinued. [...] Read more.
Background: The main aim of our study involves the analysis of reasons and risk factors for perioperative treatment discontinuation in patients with symptomatic uterine fibroids (UFs) who were qualified for magnetic resonance-guided high-intensity focused ultrasound (MR-HIFU) and in whom the procedure was discontinued. Methods: The presented research included 372 women who were primarily eligible for MR-HIFU, but the procedure was interrupted. The reasons and risk factors for treatment discontinuation were analyzed. A statistical comparison of two cohorts (patients in whom the treatment was discontinued and completed) was conducted based on epidemiological factors, UF characteristics and the implementation of uterotonics. Results: The mean discontinuation rate was 18.28% (n = 68). The main reason was the malposition of the intestines (52.94% of all cases). The thermoablation of subserosal UFs was a statistically significant risk factor of perioperative treatment discontinuation (OR 4.62, CI 95% 2.04–10.56), while the therapy of intramural UFs considerably decreased the risk (OR 0.21, CI 95% 0.08–0.51). The volume of the targeted UF was negatively correlated with the risk of discontinuation (OR 0.991, CI 95% 0.986–0.996). Augmentation with oxytocin, but not misoprostol, during the procedure significantly decreased the risk of potential discontinuation (OR 0.15, CI 95% 0.045–0.387, p < 0.001). Conclusion: Although the discontinuation rate seems to be relatively low, further prospective randomized trials are needed to confirm our results. The establishment of particular eligibility criteria for the treatment is a crucial issue in this area. Resigning from the procedure in cases at a high risk of discontinuation might increase patient safety and shorten the time to introduce the most appropriate therapy. Full article
(This article belongs to the Special Issue Clinical Management of Uterine Fibroids)
Back to TopTop